{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:13:49Z","timestamp":1793056429967,"version":"4.5.0"},"reference-count":86,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    Osteoporosis is a chronic skeletal disorder in which reduced bone strength confers sustained fracture risk, often necessitating long-term pharmacotherapy with a multi-phase approach rather than a single \u201cone and done\u201d drug choice. Contemporary guidelines increasingly advocate a treat-to-target (TTT), goal-directed approach: clinicians define an explicit target, most often a total hip\n                    <jats:italic toggle=\"yes\">T<\/jats:italic>\n                    -score threshold that corresponds to a lower fracture risk than baseline; select initial therapy according to baseline risk; and reassess and adjust treatment intensity until that target is achieved and maintained. Within this framework, sequential strategies are central. Anabolic-first sequences (e.g., abaloparatide or teriparatide followed by alendronate, or romosozumab followed by alendronate or denosumab) consistently produce larger and more durable gains in bone mineral density and fracture risk reduction in very-high-risk patients than antiresorptive monotherapy. Transitions from long-term bisphosphonates to teriparatide are complicated by transient increased remodeling and modest hip BMD responses, whereas switching to romosozumab yields more robust bone mineral density (BMD) gains at the hip. Notably, denosumab discontinuation demands structured bisphosphonate \u201cexit\u201d therapy to avoid rebound bone loss and multiple vertebral fractures. Across all pathways, rare but serious adverse events (e.g., atypical femoral fractures, medication-related osteonecrosis of the jaw, cardiovascular events), patient adherence and persistence, and insurance coverage constraints strongly shape the feasibility and desirability of specific regimens. This narrative review synthesizes mechanistic and clinical evidence underlying TTT osteoporosis care, summarizes the evidence base for sequential osteoporosis pharmacotherapy, and proposes practical strategies to help clinicians choose, transition, and discontinue therapies while preserving skeletal gains and minimizing harm over decades of longitudinal osteoporosis care.\n                  <\/jats:p>","DOI":"10.1177\/1759720x261466911","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:59:07Z","timestamp":1784703547000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal osteoporosis therapy: treat-to-target and sequential strategies\u2014a narrative review"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6785-9744","authenticated-orcid":false,"given":"Irakli","family":"Tskhakaia","sequence":"first","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9246-6200","authenticated-orcid":false,"given":"Maria I.","family":"Danila","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, SHEL Suite 178G, 1825 University Blvd, Birmingham, AL 35294, USA"},{"name":"Geriatric Research Education and Clinical Center, Birmingham Atlanta VA Medical Center, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"2","key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-0038-1660790","article-title":"Osteoporosis: current concepts","volume":"6","author":"Akkawi I","year":"2018","unstructured":"Akkawi I, Zmerly H. Osteoporosis: current concepts. Joints 2018; 6(2): 122\u2013127.","journal-title":"Joints"},{"issue":"1","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund E","year":"2013","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013; 8(1): 136.","journal-title":"Arch Osteoporos"},{"issue":"7","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/jgs.15870","article-title":"Functional outcomes after hip fracture in independent community-dwelling patients","volume":"67","author":"Ouellet JA","year":"2019","unstructured":"Ouellet JA, Ouellet GM, Romegialli AM, et al. Functional outcomes after hip fracture in independent community-dwelling patients. J Am Geriatr Soc 2019; 67(7): 1386\u20131392.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff MS","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 2022; 33(10): 2049\u20132102.","journal-title":"Osteoporos Int"},{"issue":"5","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4158\/GL-2020-0524","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update executive summary","volume":"26","author":"Camacho PM","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update executive summary. Endocr Pract 2020; 26(5): 564\u2013570.","journal-title":"Endocr Pract"},{"issue":"3","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update","volume":"105","author":"Shoback D","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab 2020; 105(3): 587\u2013594.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_4_8_2","article-title":"Advances in the management of osteoporosis","volume":"390","author":"Hoong CWS","year":"2025","unstructured":"Hoong CWS, Saul D, Khosla S, et al. Advances in the management of osteoporosis. BMJ 2025; 390: e081250.","journal-title":"BMJ"},{"issue":"2","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3803\/EnM.2021.970","article-title":"Operationalizing treat-to-target for osteoporosis","volume":"36","author":"Lewiecki EM.","year":"2021","unstructured":"Lewiecki EM. Operationalizing treat-to-target for osteoporosis. Endocrinol Metab (Seoul, Korea) 2021; 36(2): 270\u2013278.","journal-title":"Endocrinol Metab (Seoul, Korea)"},{"issue":"2","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11914-017-0350-7","article-title":"Osteoporosis: treat-to-target","volume":"15","author":"Lewiecki EM.","year":"2017","unstructured":"Lewiecki EM. Osteoporosis: treat-to-target. Curr Osteoporos Rep 2017; 15(2): 103\u2013109.","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings SR","year":"2017","unstructured":"Cummings SR, Cosman F, Lewiecki EM, et al. Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res 2017; 32(1): 3\u201310.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman F","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R, et al. Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res 2024; 39(10): 1393\u20131405.","journal-title":"J Bone Miner Res"},{"issue":"16","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman F","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375(16): 1532\u20131543.","journal-title":"N Engl J Med"},{"issue":"9","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/jbmr\/zjae116","article-title":"Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension","volume":"39","author":"Cosman F","year":"2024","unstructured":"Cosman F, Oates M, Betah D, et al. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. J Bone Miner Res 2024; 39(9): 1268\u20131277.","journal-title":"J Bone Miner Res"},{"issue":"15","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag KG","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017; 377(15): 1417\u20131427.","journal-title":"N Engl J Med"},{"issue":"7","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller PD","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016; 316(7): 722\u2013733.","journal-title":"JAMA"},{"issue":"8","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24\u2009months of alendronate after 18\u2009months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone HG","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24\u2009months of alendronate after 18\u2009months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 2018; 103(8): 2949\u20132957.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S2213-8587(19)30255-4","article-title":"Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial","volume":"7","author":"Tsai JN","year":"2019","unstructured":"Tsai JN, Lee H, David NL, et al. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol 2019; 7(10): 767\u2013775.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.180115","article-title":"Warning of an increased risk of vertebral fracture after stopping denosumab","volume":"190","author":"Symonds C","year":"2018","unstructured":"Symonds C, Kline G. Warning of an increased risk of vertebral fracture after stopping denosumab. Can Med Assoc J 2018; 190(16): E485\u2013E486.","journal-title":"Can Med Assoc J"},{"issue":"2","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3803\/EnM.2021.1369","article-title":"Discontinuing denosumab: can it be done safely? A review of the literature","volume":"37","author":"Tay WL","year":"2022","unstructured":"Tay WL, Tay D. Discontinuing denosumab: can it be done safely? A review of the literature. Endocrinol Metab (Seoul, Korea) 2022; 37(2): 183\u2013194.","journal-title":"Endocrinol Metab (Seoul, Korea"},{"issue":"1","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi E","year":"2021","unstructured":"Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 2021; 106(1): 264\u2013281.","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/archinte.167.15.1641","article-title":"Single-site vs multisite bone density measurement for fracture prediction","volume":"167","author":"Leslie WD.","year":"2007","unstructured":"Leslie WD. Single-site vs multisite bone density measurement for fracture prediction. Arch Intern Med 2007; 167(15): 1641\u20131647.","journal-title":"Arch Intern Med"},{"issue":"1","key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"101452","DOI":"10.1016\/j.jocd.2023.101452","article-title":"Clinical use of trabecular bone score: the 2023 ISCD official positions","volume":"27","author":"Goel H","year":"2024","unstructured":"Goel H, Binkley N, Boggild M, et al. Clinical use of trabecular bone score: the 2023 ISCD official positions. J Clin Densitom 2024; 27(1): 101452.","journal-title":"J Clin Densitom"},{"key":"e_1_3_4_24_2","unstructured":"International Society for Clinical Densitometry. 2023 ISCD official positions\u2014adult 2024 https:\/\/iscd.org\/wp-content\/uploads\/2024\/03\/2023-ISCD-Adult-Positions.pdf (2026 accessed 13 May 2026)."},{"issue":"9","key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00198-023-06817-4","article-title":"Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging","volume":"34","author":"Shevroja E","year":"2023","unstructured":"Shevroja E, Reginster JY, Lamy O, et al. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporos Int 2023; 34(9): 1501\u20131529.","journal-title":"Osteoporos Int"},{"issue":"11","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"for the Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem A","year":"2017","unstructured":"Qaseem A, Forciea MA, McLean RM, et al.; for the Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017; 166(11): 818\u2013839.","journal-title":"Ann Intern Med"},{"issue":"1","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.afos.2024.02.001","article-title":"Asia-Pacific consensus on long-term and sequential therapy for osteoporosis","volume":"10","author":"Tai TW","year":"2024","unstructured":"Tai TW, Chen HY, Shih CA, et al. Asia-Pacific consensus on long-term and sequential therapy for osteoporosis. Osteoporos Sarcopenia 2024; 10(1): 3\u201310.","journal-title":"Osteoporos Sarcopenia"},{"issue":"5","key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society","volume":"105","author":"Van de Laarschot DM","year":"2020","unstructured":"Van de Laarschot DM, McKenna MJ, Abrahamsen B, et al. Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society. J Clin Endocrinol Metab 2020; 105(5): 1682\u20131699.","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim IW","year":"2020","unstructured":"Sim IW, Borromeo GL, Tsao C, et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. J Clin Oncol 2020; 38(26): 2971\u20132980.","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jocd.2007.05.002","article-title":"A generalized least significant change for individuals measured on different DXA systems","volume":"10","author":"Shepherd JA","year":"2007","unstructured":"Shepherd JA, Lu Y. A generalized least significant change for individuals measured on different DXA systems. J Clin Densitom 2007; 10(3): 249\u2013258.","journal-title":"J Clin Densitom"},{"key":"e_1_3_4_31_2","unstructured":"U.S. Food and Drug Administration. FDA qualifies total hip bone mineral density (BMD) as a surrogate endpoint for osteoporosis drug development https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-qualifies-total-hip-bone-mineral-density-bmd-surrogate-endpoint-osteoporosis-drug-development (2025 accessed 13 May 2026)."},{"key":"e_1_3_4_32_2","unstructured":"U.S. Department of Veterans Affairs Pharmacy Benefits Management Services Medical Advisory Panel VISN Pharmacist Executives. Clinical guidance on the sequential and combined use of antiresorptive and anabolic agents for osteoporosis. U.S. Department of Veterans Affairs https:\/\/www.pbm.va.gov\/PBM\/clinicalguidance\/clinicalrecommendations\/Osteoporosis_Sequential_Combined_Antiresorptive_Anabolic_Agents.pdf (2022 accessed 13 May 2026)."},{"issue":"8","key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings SR","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361(8): 756\u2013765.","journal-title":"N Engl J Med"},{"issue":"18","key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black DM","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809\u20131822.","journal-title":"N Engl J Med"},{"issue":"5","key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens P","year":"2018","unstructured":"Geusens P, Marin F, Kendler DL, et al. Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial. J Bone Miner Res 2018; 33(5): 783\u2013794.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"e_1_3_4_36_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299673","article-title":"Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico","volume":"20","author":"Diaz Martinez JP","year":"2025","unstructured":"Diaz Martinez JP, Aubry De Maraumont T, Natty S\u00e1nchez E, et al. Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico. PLoS One 2025; 20(2): e0299673.","journal-title":"PLoS One"},{"issue":"11","key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1210\/jc.2019-00924","article-title":"Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use","volume":"104","author":"Lyu H","year":"2019","unstructured":"Lyu H, Zhao SS, Yoshida K, et al. Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use. J Clin Endocrinol Metab 2019; 104(11): 5611\u20135620.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M22-0684","article-title":"Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians","volume":"176","author":"Ayers C","year":"2023","unstructured":"Ayers C, Kansagara D, Lazur B, et al. Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 2023; 176(2): 182\u2013195.","journal-title":"Ann Intern Med"},{"issue":"6","key":"e_1_3_4_39_2","doi-asserted-by":"crossref","DOI":"10.7326\/L24-0118","article-title":"Update alert: effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians","volume":"177","author":"Ayers C","year":"2024","unstructured":"Ayers C, Ward R, Kansagara D. Update alert: effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 2024; 177(6): eL230118.","journal-title":"Ann Intern Med"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"102425","DOI":"10.1016\/j.eclinm.2024.102425","article-title":"Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials","volume":"68","author":"Han YX","year":"2024","unstructured":"Han YX, Mo YY, Wu HX, et al. Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials. EClinicalMedicine 2024; 68: 102425.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"e_1_3_4_41_2","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziaf165","article-title":"A systematic review of combination treatment strategies for osteoporosis","volume":"9","author":"Nayak S","year":"2025","unstructured":"Nayak S, Greenspan SL. A systematic review of combination treatment strategies for osteoporosis. JBMR Plus 2025; 9(12): ziaf165.","journal-title":"JBMR Plus"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"888208","DOI":"10.3389\/fphar.2022.888208","article-title":"Efficacy of the combination of teriparatide and denosumab in the treatment of postmenopausal osteoporosis: a meta-analysis","volume":"13","author":"Sun Y","year":"2022","unstructured":"Sun Y, Li Y, Li J, et al. Efficacy of the combination of teriparatide and denosumab in the treatment of postmenopausal osteoporosis: a meta-analysis. Front Pharmacol 2022; 13: 888208.","journal-title":"Front Pharmacol"},{"issue":"3","key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00198-020-05780-8","article-title":"Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden","volume":"32","author":"S\u00f6reskog E","year":"2021","unstructured":"S\u00f6reskog E, Lindberg I, Kanis JA, et al. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporos Int 2021; 32(3): 585\u2013594.","journal-title":"Osteoporos Int"},{"issue":"7","key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00198-024-07043-2","article-title":"Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium","volume":"35","author":"Gielen E","year":"2024","unstructured":"Gielen E, Bergmann P, Body JJ, et al. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium. Osteoporos Int 2024; 35(7): 1173\u20131183.","journal-title":"Osteoporos Int"},{"issue":"10","key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1753-4887.2001.tb06957.x","article-title":"The bone remodeling transient: interpreting interventions involving bone-related nutrients","volume":"59","author":"Heaney RP.","year":"2001","unstructured":"Heaney RP. The bone remodeling transient: interpreting interventions involving bone-related nutrients. Nutr Rev 2001; 59(10): 327\u2013334.","journal-title":"Nutr Rev"},{"issue":"8","key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","article-title":"Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review","volume":"41","author":"Fardellone P","year":"2019","unstructured":"Fardellone P, Lello S, Cano A, et al. Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther 2019; 41(8): 1576\u20131588.","journal-title":"Clin Ther"},{"issue":"11","key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","article-title":"Persistence and adherence to parenteral osteoporosis therapies: a systematic review","volume":"31","author":"Koller G","year":"2020","unstructured":"Koller G, Goetz V, Vandermeer B, et al. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 2020; 31(11): 2093\u20132102.","journal-title":"Osteoporos Int"},{"issue":"10","key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","article-title":"Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis","volume":"26","author":"Karlsson L","year":"2015","unstructured":"Karlsson L, Lundkvist J, Psachoulia E, et al. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 2015; 26(10): 2401\u20132411.","journal-title":"Osteoporos Int"},{"issue":"1","key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11657-020-00733-4","article-title":"Adherence to and persistence with zoledronic acid treatment for osteoporosis-reasons for early discontinuation","volume":"15","author":"Sp\u00e5ngeus A","year":"2020","unstructured":"Sp\u00e5ngeus A, Johansson S, Woisetschl\u00e4ger M. Adherence to and persistence with zoledronic acid treatment for osteoporosis-reasons for early discontinuation. Arch Osteoporos 2020; 15(1): 58.","journal-title":"Arch Osteoporos"},{"issue":"19","key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer RM","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434\u20131441.","journal-title":"N Engl J Med"},{"issue":"10102","key":"e_1_3_4_51_2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl BL","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet Lond Engl 2017; 390(10102): 1585\u20131594.","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"e_1_3_4_52_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11914-026-00967-0","article-title":"Sequential versus step-therapy approaches for osteoporosis management in orthopedic subspecialties","volume":"24","author":"Salman SG","year":"2026","unstructured":"Salman SG, Phadke R, Burnett J, et al. Sequential versus step-therapy approaches for osteoporosis management in orthopedic subspecialties. Curr Osteoporos Rep 2026; 24(1): 19.","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"e_1_3_4_53_2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/art.70002","article-title":"Romosozumab and denosumab combination therapy after denosumab in postmenopausal osteoporosis","volume":"78","author":"Adami G","year":"2026","unstructured":"Adami G, Pollastri F, Fassio A, et al. Romosozumab and denosumab combination therapy after denosumab in postmenopausal osteoporosis. Arthritis Rheumatol 2026; 78(5): 1176\u20131183.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"e_1_3_4_54_2","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae016","article-title":"Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study","volume":"8","author":"Adami G","year":"2024","unstructured":"Adami G, Pedrollo E, Rossini M, et al. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study. JBMR Plus 2024; 8(4): ziae016.","journal-title":"JBMR Plus"},{"issue":"13","key":"e_1_3_4_55_2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black DM","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349(13): 1207\u20131215.","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_3_4_56_2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman F","year":"2011","unstructured":"Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis. J Bone Miner Res 2011; 26(3): 503\u2013511.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"e_1_3_4_57_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/biochem5030031","article-title":"Osteoporosis: focus on bone remodeling and disease types","volume":"5","author":"Castellani C","year":"2025","unstructured":"Castellani C, De Martino E, Scapato P. Osteoporosis: focus on bone remodeling and disease types. BioChem 2025; 5(3): 31.","journal-title":"BioChem"},{"issue":"5","key":"e_1_3_4_58_2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.20945\/2359-3997000000566","article-title":"Anabolic therapy for osteoporosis: update on efficacy and safety","volume":"66","author":"Bandeira L","year":"2022","unstructured":"Bandeira L, Lewiecki EM. Anabolic therapy for osteoporosis: update on efficacy and safety. Arch Endocrinol Metab 2022; 66(5): 707\u2013716.","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"e_1_3_4_59_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1186\/s12967-023-04563-z","article-title":"Romosozumab in osteoporosis: yesterday, today and tomorrow","volume":"21","author":"Wu D","year":"2023","unstructured":"Wu D, Li L, Wen Z, et al. Romosozumab in osteoporosis: yesterday, today and tomorrow. J Transl Med 2023; 21(1): 668.","journal-title":"J Transl Med"},{"issue":"3","key":"e_1_3_4_60_2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jc.2012-3680","article-title":"Treat-to-target for osteoporosis: is now the time?","volume":"98","author":"Lewiecki EM","year":"2013","unstructured":"Lewiecki EM, Cummings SR, Cosman F. Treat-to-target for osteoporosis: is now the time? J Clin Endocrinol Metab 2013; 98(3): 946\u2013953.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"e_1_3_4_61_2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/jbmr\/zjae126","article-title":"The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24\u2009mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project","volume":"39","author":"Vilaca T","year":"2024","unstructured":"Vilaca T, Schini M, Lui LY, et al. The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24\u2009mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project. J Bone Miner Res 2024; 39(10): 1434\u20131442.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"e_1_3_4_62_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00198-019-04975-y","article-title":"Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study","volume":"30","author":"Leslie WD","year":"2019","unstructured":"Leslie WD, Martineau P, Bryanton M, et al. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study. Osteoporos Int 2019; 30(7): 1445\u20131453.","journal-title":"Osteoporos Int"},{"issue":"12","key":"e_1_3_4_63_2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00198-023-06889-2","article-title":"Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis","volume":"34","author":"Hong N","year":"2023","unstructured":"Hong N, Shin S, Lee S, et al. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis. Osteoporos Int 2023; 34(12): 2059\u20132067.","journal-title":"Osteoporos Int"},{"issue":"6","key":"e_1_3_4_64_2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00198-023-06708-8","article-title":"Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension","volume":"34","author":"Hans D","year":"2023","unstructured":"Hans D, McDermott M, Huang S, et al. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension. Osteoporos Int 2023; 34(6): 1075\u20131084.","journal-title":"Osteoporos Int"},{"issue":"7","key":"e_1_3_4_65_2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jbmr\/zjae068","article-title":"Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project","volume":"39","author":"Schini M","year":"2024","unstructured":"Schini M, Vilaca T, Lui LY, et al. Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project. J Bone Miner Res 2024; 39(7): 867\u2013876.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"e_1_3_4_66_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40520-024-02826-3","article-title":"Recommendations for the optimal use of bone forming agents in osteoporosis","volume":"36","author":"Veronese N","year":"2024","unstructured":"Veronese N, Briot K, Gua\u00f1abens N, et al. Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clin Exp Res 2024; 36(1): 167.","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"e_1_3_4_67_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.20945\/2359-3997000000564","article-title":"The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence","volume":"66","author":"Chandran M.","year":"2022","unstructured":"Chandran M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab 2022; 66(5): 724\u2013738.","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"e_1_3_4_68_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy","volume":"2","author":"Leder BZ.","year":"2018","unstructured":"Leder BZ. Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. JBMR Plus 2018; 2(2): 62\u201368.","journal-title":"JBMR Plus"},{"issue":"20","key":"e_1_3_4_69_2","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag KG","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357(20): 2028\u20132039.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_4_70_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler DL","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25(1): 72\u201381.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"e_1_3_4_71_2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline","volume":"104","author":"Eastell R","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2019; 104(5): 1595\u20131622.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"e_1_3_4_72_2","article-title":"Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial","volume":"7","author":"Lee CC","year":"2024","unstructured":"Lee CC, Wang CY, Yen HK, et al. Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial. JAMA Netw Open 2024; 7(11): e2443899.","journal-title":"JAMA Netw Open"},{"issue":"9999","key":"e_1_3_4_73_2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder BZ","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet Lond Engl 2015; 386(9999): 1147\u20131155.","journal-title":"Lancet Lond Engl"},{"issue":"7","key":"e_1_3_4_74_2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-007-0542-6","article-title":"The remodeling transient and the calcium economy","volume":"19","author":"Aloia JF","year":"2008","unstructured":"Aloia JF, Arunabh-Talwar S, Pollack S, et al. The remodeling transient and the calcium economy. Osteoporos Int 2008; 19(7): 1001\u20131009.","journal-title":"Osteoporos Int"},{"issue":"3","key":"e_1_3_4_75_2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen S","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008; 93(3): 852\u2013860.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"e_1_3_4_76_2","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller PD","year":"2008","unstructured":"Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008; 93(10): 3785\u20133793.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"e_1_3_4_77_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane E","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29(1): 1\u201323.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"e_1_3_4_78_2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00198-023-06768-w","article-title":"The effect of teriparatide on fracture healing after atypical femoral fracture: a systematic review and meta-analysis","volume":"34","author":"Byun SE","year":"2023","unstructured":"Byun SE, Lee KJ, Shin WC, et al. The effect of teriparatide on fracture healing after atypical femoral fracture: a systematic review and meta-analysis. Osteoporos Int 2023; 34(8): 1323\u20131334.","journal-title":"Osteoporos Int"},{"issue":"3","key":"e_1_3_4_79_2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00402-023-05171-8","article-title":"The effect of teriparatide on patients with atypical femur fractures: a systematic review and meta-analysis","volume":"144","author":"Salamah HM","year":"2024","unstructured":"Salamah HM, Abualkhair KA, Kamal SK, et al. The effect of teriparatide on patients with atypical femur fractures: a systematic review and meta-analysis. Arch Orthop Trauma Surg 2024; 144(3): 1091\u20131106.","journal-title":"Arch Orthop Trauma Surg"},{"issue":"3","key":"e_1_3_4_80_2","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler D","year":"2020","unstructured":"Kendler D, Chines A, Clark P, et al. Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab 2020; 105(3): e255\u2013e264.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"e_1_3_4_81_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler RA","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016; 31(1): 16\u201335.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"e_1_3_4_82_2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer JA","year":"2007","unstructured":"Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18(8): 1023\u20131031.","journal-title":"Osteoporos Int"},{"issue":"1","key":"e_1_3_4_83_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-010-1274-6","article-title":"Oral bisphosphonate compliance and persistence: a matter of choice?","volume":"22","author":"Silverman SL","year":"2011","unstructured":"Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 2011; 22(1): 21\u201326.","journal-title":"Osteoporos Int"},{"issue":"4","key":"e_1_3_4_84_2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027049","article-title":"Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review","volume":"9","author":"Fatoye F","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, et al. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 2019; 9(4): e027049.","journal-title":"BMJ Open"},{"key":"e_1_3_4_85_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2008.12.002","article-title":"Impact of osteoporosis treatment adherence on fracture rates in North America and Europe","volume":"122","author":"Siris ES","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122(2 Suppl.): S3\u201313.","journal-title":"Am J Med"},{"issue":"1","key":"e_1_3_4_86_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11657-021-00932-7","article-title":"Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland","volume":"16","author":"Walsh ME","year":"2021","unstructured":"Walsh ME, Fahey T, Moriarty F. Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland. Arch Osteoporos 2021; 16(1): 71.","journal-title":"Arch Osteoporos"},{"issue":"11","key":"e_1_3_4_87_2","first-page":"1178","article-title":"Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. Medicare Population","volume":"23","author":"Keshishian A","year":"2017","unstructured":"Keshishian A, Boytsov N, Burge R, et al. Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. Medicare Population. J Manag Care Spec Pharm 2017; 23(11): 1178\u20131190.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X261466911","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X261466911","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X261466911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:46:22Z","timestamp":1785019582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X261466911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":86,"alternative-id":["10.1177\/1759720X261466911"],"URL":"https:\/\/doi.org\/10.1177\/1759720x261466911","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"1759720X261466911"}}